The Children’s Cancer Therapy Development Institute (cc-TDI), Champions Oncology, and The Jackson Laboratory offer rapid, cost-effective services to the pharma, biopharma and biotech industry– speeding the right drug to the right pediatric cancer whenever possible.
Hackensack, NJ – November 13, 2019 – Champions Oncology (NASDAQ: CSBR), an end-to-end R&D Oncology solutions company announced today that they have entered into a strategic partnership with PhenoVista Biosciences.
HACKENSACK, NJ – May 30, 2019 – Champions Oncology, Inc. (NASDAQ: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced they have partnered with TransCure bioServices to expand the pharmacology operations of Champions’ translational oncology tools throughout Europe.
Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2019
Hackensack, NJ – September 13, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced its financial results for the first fiscal quarter ended July 31, 2018.